Trial Profile
A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EMILIA
- Sponsors Roche
- 07 Jan 2020 Results of an individual patient-level data pooled analysis of trials testing T-DM1 in the advanced setting investigating T-DM1-induced cardiotoxicity, with a focus on the incidence of CEs, clinical presentation of CEs, impact on treatment continuity, reversibility as well as in any potential risk factors that could aid in patient selection and follow-up published in the European Journal of Cancer
- 14 Dec 2019 Results of systematic review and meta-analysis of phase 3 randomized controlled trials (EMILIA, GATSBY, KRISTINE, MARIANNE, and TH3RESA) presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 14 Dec 2019 Results of systemic review and meta analysis assessing Relative risk of grade 3 and higher hematological toxicities with trastuzumab emtansine presented at the 42nd Annual San Antonio Breast Cancer Symposium